Results 41 to 50 of about 1,619,240 (186)
Vildagliptin and its role in the treatment of diabetes mellitus
Сахарный диабет, 2010 Type 2 diabetes mellitus is a most serious medical problem throughout the world. Traditional hypoglycemic agents do not ensure long-term control ofglycemia and fail to affect the natural course of DM.
Yury Shavkatovich Khalimov
doaj +1 more source
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
Drug Design, Development and Therapy, 2016 Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of ...
Hu MH, Zheng CL, Gao F
doaj
, 1982 Department of Chemistry, Lucknow University, Lucknow-226 007 Division of Experimental Medicine, C. D. R. I., Lucknow Manuscript received 9 March 1981, revised 18 March 1982 accepted 12 August 1982 Search for New Hypoglycemic Agents.
(Miss) KIRAN BALA GUPTA +2 more
core +1 more source
Pharmacotherapy of Oral Hypoglycemic Agents
, 1992 The use of sulfonylurea in conjunction with a diet and exercise regimen continues to be the primary treatment modality for obese type II diabetics in the United States. These agents work to lower plasma glucose by several proposed mechanisms. Pancreatic
Randell K. Miyahara
core +1 more source
SYNTHESIS AND BIOLOGICAL ACTIVITIES OF SOME NEW ARYLSULPHONYLUREA AND THIOUREA DERIVATIVES
Zagazig Journal of Pharmaceutical Sciences, 1999 Certain arylsulphonylureas and thioureas derivatives were synthesized to be tested as hypoglycemic and antimicrobial agents in comparison with glibinclamide and sulphanilamide, respectively.
Mansour Abou-Kull , Magdy Amer
doaj +1 more source
Disparity in cost of oral hypoglycemic agents available in Indian market [PDF]
, 2019 Background: Diabetes is one of the most common non-communicable disease worldwide, of which India has been crowned with the title of “diabetes capital of the world”. On an average a person spends 20% of his or her income for the treatment of diabetes per
., Soni +2 more
core +1 more source
Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes
, 2017 Clinical Question: Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse
Rutten, Guy E.H.M. +10 more
core +1 more source
Frontiers in ImmunologyWith the steadily rising incidence of lung cancer and diabetes mellitus, both of them are increasingly becoming prominent global health concerns. Treatment options for lung cancer to improve prognosis and reduce the pain and financial burden of patients ...
Qian Wang +9 more
doaj +1 more source
Linchuang shenzangbing zazhiA rising incidence of acute kidney injury (AKI) may lead to longer hospitalization stays and even greater mortality. Diabetes is an independent risk factor for AKI and using hypoglycemic agents has been a fundamental glycemic control in diabetics ...
Dan-ning Guo +2 more
doaj +1 more source
Potential risks and pharmacological safety features of hypoglycemic drugs
, 2021 For the treatment of diabetes, insulin preparations, synthetic hypoglycemic agents, herbal medicine and compulsory adherence to the diet. Oral hypoglycemic agents belong to different chemical classes: sulfonylurea derivatives, biguanides ...
Svyshch, O. +6 more
core